Despite significant advancements in medical therapeutic approaches, such as corticosteroids, immunosuppressants and anti‐TNF‐α monoclonal antibodies (mAbs), existing therapies for inflammatory bowel disease (IBD) still face limitations in achieving satisfactory response and remission rates.1 The gene discussed is TNF; the disease is inflammatory bowel disease.